Order of the National Green Tribunal in the matter of In Re: News Item titled "Futala Lake’s charm fades amid neglect and poor maintenance appearing in ‘The Times of India’ dated 25.05.2025". The original application was registered suo-motu based on the news item titled "Futala Lake’s charm fades amid neglect …
The Pharmaceutical Research and Manufacturers of America and the United States India Business Council are miffed over the recent Novartis judgment of the Supreme Court (SC) of India. For us, however, this ruling on the question of the patentability of the beta crystalline form of Imatinib Mesylate (IM) is one …
Supreme Court judgement dated 01-04-2013:in Appeal Civil No. 2706-2716/2013 @ SLP(C) 20539-20549/2009 Novartis AG Vs. Union of India and ors (Patent/Cancer Drug).
The compulsory licence issued to Natco for manufacture of the anti-cancer drug Nexavar is a landmark decision on many grounds – the first one in India since the 2005 amendment to the 1970 Patents Act and the fi rst in the world issued to a private party. There are some …
India’s pharmaceuticals industry tends to be in the eye of the storm for one reason or the other. If it is not about its aggressive generics thrust globally, it is about high-profile patent infringement cases at home and abroad. The gamut of laws governing the sector, therefore, are keenly watched …
Per se is a straightforward term meaning by or in itself. Those who use it are pretty clear what the Latin-origin term signifies.And that’s what our lawmakers must have also believed when they used it in the 2005 amendment to India’s Patent Act. But unaccountably this particular term has turned …
Mashelkar report says modified organisms are intellectual property THE expert group on patent law headed by R A Mashelkar has recommended that microbes like bacteria, fungi and virus should be patented if they have been modified. The committee has also said India cannot limit its patents to new chemical substances …
When pharmaceutical company Novartis challenged the rejection of its patent application for the leukemia drug Gleevec in Novartis AG v. Union of India, it became the first major legal challenge to India’s newly amended patent law. In 2005, India purportedly made the final changes required to bring its intellectual property …
